The Life of Aducanumab: A Potential Novel Alzheimer’s Disease Drug

On October 22nd, 2019, headlines read “Biogen plans regulatory filing for Aducanumab for Alzheimer’s disease based on new analysis of larger dataset from phase 3 studies”. Alzheimer’s disease (AD) is a devastating neurodegenerative disease characterized by cognitive dysfunction and memory loss. It is the 6th leading cause of adult deaths in the United States. Biogen … Continue reading The Life of Aducanumab: A Potential Novel Alzheimer’s Disease Drug